Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PI4KA | P42356 | 1/20 | 0.66 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.66 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.66 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.66 |
| ▸ | ADK | P55263 | 14/20 | 0.60 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.50 |
| ▸ | HASPIN | Q8TF76 | 1/20 | 0.49 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | GALR3 | O60755 | 1/20 | 0.48 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.48 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.47 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL90988 | 1.00 | PI4KA (0.66) | PI4KAPI4K2BPI4K2API4KBADK | |
| SCHEMBL67726 | 1.00 | PI4KA (0.66) | PI4KAPI4K2BPI4K2API4KBADK | |
| SCHEMBL18297604 | 0.96 | ADK (0.62) | PI4KAPI4K2BPI4K2API4KBADK | |
| Iodotubercidin SCHEMBL18297690 | 0.94 | ADK (0.67) | PI4KAPI4K2BPI4K2API4KBADK | |
| SCHEMBL18297471 | 0.91 | ADK (0.65) | PI4KAPI4K2BPI4K2API4KBADK | |
| SCHEMBL90990 | 0.88 | ADK (0.67) | PI4KAPI4K2BPI4K2API4KBADK | |
| SCHEMBL67029 | 0.88 | ADK (0.67) | PI4KAPI4K2BPI4K2API4KBADK | |
| SCHEMBL60684 | 0.88 | ADK (0.67) | PI4KAPI4K2BPI4K2API4KBADK | |
| SCHEMBL31526134 | 0.88 | PI4KA (0.66) | PI4KAPI4K2BPI4K2API4KBADK | |
| SCHEMBL18571721 | 0.88 | PI4KA (0.66) | PI4KAPI4K2BPI4K2API4KBADK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260000698-A1 | SARS-COV-2 NSP14 METHYLTRANSFERASE INHIBITORS | UNIV MINNESOTA (US) | 2026-01-01 | — | — | US | disclosed |
| WO-2023230061-A2 | SARS-COV-2 NSP14 METHYLTRANSFERASE INHIBITORS | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2023-11-30 | — | — | WO | disclosed |
| CN-106661031-B | Pyrrolopyrimidine compounds or its salt, pharmaceutical composition and application containing it | 大鹏药品工业株式会社 | 2019-07-23 | — | — | CN | disclosed |
| US-20190010158-A1 | ANTITUMOR EFFECT POTENTIATOR COMPRISING PYRROLOPYRIMIDINE COMPOUND | TAIHO PHARMACETUICAL CO., LTD. (JP) | 2019-01-10 | — | — | US | disclosed |
| US-10174040-B2 | Pyrrolopyrimidine compound or salt thereof and compositions containing the pyrrolopyrimidine compound or salt thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2019-01-08 | — | — | US | disclosed |
| EP-3395345-A1 | ANTITUMOR EFFECT POTENTIATOR COMPRISING PYRROLOPYRIMIDINE COMPOUND | Taiho Pharmaceutical Co., Ltd. (JP) | 2018-10-31 | — | — | EP | disclosed |
| US-20180162864-A1 | PYRROLOPYRIMIDINE COMPOUND OR SALT THEREOF AND COMPOSITIONS CONTAINING THE PYRROLOPYRIMIDINE COMPOUND OR SALT THEREOF | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2018-06-14 | — | — | US | disclosed |
| US-9963456-B2 | Pyrrolopyrimidine compound or salt thereof and compositions containing the pyrrolopyrimidine compound or salt thereof | TAIHO PHARMACEUTICAL CO., LTD (JP) | 2018-05-08 | — | — | US | disclosed |
| EP-3103802-B1 | NOVEL PYRROLOPYRIMIDINE COMPOUND OR SALT THEREOF, PHARMACEUTICAL COMPOSITION CONTAINING SAME, ESPECIALLY AGENT FOR PREVENTION AND/OR TREATMENT OF TUMORS ETC BASED ON NAE INHIBITORY EFFECT | TAIHO PHARMACEUTICAL CO LTD (JP) | 2017-11-08 | — | — | EP | disclosed |
| US-20170066772-A1 | NOVEL PYRROLOPYRIMIDINE COMPOUND OR SALT THEREOF, PHARMACEUTICAL COMPOSITION CONTAINING SAME, ESPECIALLY AGENT FOR PREVENTION AND/OR TREATMENT OF TUMORS ETC BASED ON NAE INHIBITORY EFFECT | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2017-03-09 | — | — | US | disclosed |
| EP-3103802-A1 | NOVEL PYRROLOPYRIMIDINE COMPOUND OR SALT THEREOF, PHARMACEUTICAL COMPOSITION CONTAINING SAME, ESPECIALLY AGENT FOR PREVENTION AND/OR TREATMENT OF TUMORS ETC BASED ON NAE INHIBITORY EFFECT | Taiho Pharmaceutical Co., Ltd. (JP) | 2016-12-14 | — | — | EP | disclosed |
| EP-1756313-B1 | SEQUENCE-SPECIFIC DETECTION OF METHYLATION IN BIOMOLECULES | MAX PLANCK GESELLSCHAFT (DE) | 2012-06-06 | — | — | EP | disclosed |
| US-8129106-B2 | Sequence-specific detection of methylation in biomolecules | Max-Planck-Geselischaft zur Forderung der Wissenschaften E.V. (DE) | 2012-03-06 | — | — | US | disclosed |
| US-20110165564-A1 | SEQUENCE-SPECIFIC DETECTION OF METHYLATION IN BIOMOLECULES | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2011-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190010158-A1 | ANTITUMOR EFFECT POTENTIATOR COMPRISING PYRROLOPYRIMIDINE COMPOUND | MCL1, TP53, DPYD | PI4KA 1037/4885PI4K2B 1636/4885PI4K2A 1468/4885 |
| US-10174040-B2 | Pyrrolopyrimidine compound or salt thereof and compositions containing the pyrrolopyrimidine compound or salt thereof | KRAS, DPYD, PSTPIP2 | PI4KA 1515/4885PI4K2B 1852/4885PI4K2A 1988/4885 |
| US-20170066772-A1 | NOVEL PYRROLOPYRIMIDINE COMPOUND OR SALT THEREOF, PHARMACEUTICAL COMPOSITION CONTAINING SAME, ESPECIALLY AGENT FOR PREVENTION AND/OR TREATMENT OF TUMORS ETC BASED ON NAE INHIBITORY EFFECT | WASHC5, NME1, NHERF1 | PI4KA 2018/4885PI4K2B 1805/4885PI4K2A 1806/4885 |
| US-20180162864-A1 | PYRROLOPYRIMIDINE COMPOUND OR SALT THEREOF AND COMPOSITIONS CONTAINING THE PYRROLOPYRIMIDINE COMPOUND OR SALT THEREOF | KRAS, DPYD, PSTPIP2 | PI4KA 1515/4885PI4K2B 1852/4885PI4K2A 1988/4885 |
| US-20260000698-A1 | SARS-COV-2 NSP14 METHYLTRANSFERASE INHIBITORS | NSUN2, SARS1, RNMT | PI4KA 2862/4885PI4K2B 2542/4885PI4K2A 3099/4885 |
| US-20110165564-A1 | SEQUENCE-SPECIFIC DETECTION OF METHYLATION IN BIOMOLECULES | DNMT1, MAT2B, AHCY | PI4KA 4743/4885PI4K2B 4739/4885PI4K2A 4799/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.